Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyethylene glycol 3350 + mannitol is an oral osmotic laxative formulation developed by Bayer, currently evaluated in Phase 4 clinical trials for the treatment of occasional constipation. The formulation combines polyethylene glycol (PEG) 3350, a non-absorbable polymer that retains water in the intestinal lumen through osmotic pressure to soften stool, with mannitol, a sugar alcohol. In this specific product development context, mannitol is utilized primarily as a flavoring agent to enhance the palatability and taste acceptability of the PEG 3350 solution, rather than as a primary active therapeutic ingredient. The combination aims to improve patient compliance by addressing the taste profile of standard PEG 3350 treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyethylene glycol 3350 + mannitol.